Department of Cardiology, the Xiamen Cardiovascular Hospital of Xiamen University, Xiamen, Fujian, China.
Department of Pharmacy, the Xiamen Cardiovascular Hospital of Xiamen University, Xiamen, Fujian, China.
Curr Mol Med. 2024;24(6):771-779. doi: 10.2174/1566524023666230418104400.
Angiopoietin-like protein 3 (ANGPTL-3) modulates lipid metabolism and the risk of coronary artery disease (CAD), especially stable angina (SA), via suppressing lipoprotein lipase (LPL). However, whether there are other mechanisms is not elucidated yet. The current research explored the modulatory roles of ANGPTL-3 on high-density lipoprotein (HDL), which further affects atherosclerotic development.
A total of 200 individuals were enrolled in the present study. Serum ANGPTL- 3 levels were detected via enzyme-linked immunosorbent assays (ELISA). Cholesterol efflux capacity induced by HDL particles was detected through H-cholesterol loading THP-1 cell.
The serum ANGPTL-3 levels presented no significant discordance between the SA group and the non-SA group, whereas the serum ANGPTL-3 levels in type 2 diabetes mellitus (T2DM) group were significantly elevated compared with those in the non-T2DM group [428.3 (306.2 to 736.8) ng/ml vs. 298.2 (156.8 to 555.6) ng/ml, p <0.05]. Additionally, the serum ANGPTL-3 levels were elevated in patients with low TG levels compared to those in patients with high TG levels [519.9 (377.6 to 809.0) ng/ml vs. 438.7 (329.2 to 681.0) ng/ml, p <0.05]. By comparison, the individuals in the SA group and T2DM group presented decreased cholesterol efflux induced by HDL particles [SA: (12.21±2.11)% vs. (15.51±2.76)%, p <0.05; T2DM: (11.24±2.13)% vs. (14.65± 3.27)%, p <0.05]. In addition, the serum concentrations of ANGPTL-3 were inversely associated with the cholesterol efflux capacity of HDL particles (r=-0.184, p <0.05). Through regression analysis, the serum concentrations of ANGPTL-3 were found to be an independent modulator of the cholesterol efflux capacity of HDL particles (standardized β=-0.172, p <0.05).
ANGPTL-3 exhibited a negative modulatory function on cholesterol efflux capacity induced by HDL particles.
血管生成素样蛋白 3(ANGPTL-3)通过抑制脂蛋白脂肪酶(LPL)来调节脂质代谢和冠心病(CAD)的风险,尤其是稳定型心绞痛(SA)。然而,其是否存在其他机制尚不清楚。本研究旨在探讨 ANGPTL-3 对高密度脂蛋白(HDL)的调节作用,后者进一步影响动脉粥样硬化的发展。
本研究共纳入 200 名个体。通过酶联免疫吸附试验(ELISA)检测血清 ANGPTL-3 水平。通过 H-胆固醇负载 THP-1 细胞检测由 HDL 颗粒诱导的胆固醇流出能力。
SA 组和非 SA 组之间的血清 ANGPTL-3 水平无显著差异,而 2 型糖尿病(T2DM)组的血清 ANGPTL-3 水平明显高于非 T2DM 组[428.3(306.2 至 736.8)ng/ml 比 298.2(156.8 至 555.6)ng/ml,p<0.05]。此外,与高 TG 水平的患者相比,低 TG 水平的患者血清 ANGPTL-3 水平升高[519.9(377.6 至 809.0)ng/ml 比 438.7(329.2 至 681.0)ng/ml,p<0.05]。相比之下,SA 组和 T2DM 组的 HDL 颗粒诱导的胆固醇流出率降低[SA:(12.21±2.11)%比(15.51±2.76)%,p<0.05;T2DM:(11.24±2.13)%比(14.65±3.27)%,p<0.05]。此外,血清 ANGPTL-3 浓度与 HDL 颗粒的胆固醇流出能力呈负相关(r=-0.184,p<0.05)。通过回归分析发现,血清 ANGPTL-3 浓度是 HDL 颗粒胆固醇流出能力的独立调节因子(标准化β=-0.172,p<0.05)。
ANGPTL-3 对 HDL 颗粒诱导的胆固醇流出能力具有负调节作用。